News

New cancer collaborations
Enlarge image

BusinessFranceSwitzerland

New cancer collaborations

30.01.2013 - Swiss 4-Antibody and Ludwig Institute will expand their cooperation, while Curie-Cancer and Genosplice Technology inked a cancer genomics pact.

The two new cancer collaborations were kicked-off yesterday. The French bioinformatics expert Genosplice Technology and the tech-transfer arm of Paris-based Institut Curie aim at developing high value-added cancer genomic approaches. GenoSplice will gain access to several Curie-Cancer technology platforms and research programmes and will contribute to the development of new products against cancer through genome mapping using its bioinformatics expertise. The partners aim to define a genomic map for prostate cancer including pathways and therapeutic options. In a second project the French will seek response biomarkers for a preclinical peptide that already has been proven effective in mouse xenograft experiments. 

On the same day, Swiss 4-Antibody AG and US-based Ludwig Institute expanded its existing cancer antibody development pact with three new targets provided by Brazilian antibody developer Recepta Biopharma SA. The partners will focus their R&D partnership on the generation of three antibodies targeting important cancer immune checkpoints. Under the terms of the agreement, 4-Antibody will use its high-throughput Retrocyte Display® technology platform to generate and produce fully human therapeutic antibody candidates. The Ludwig Institute will validate the new constructs and then, together with Recepta Biopharma, will take these antibody drugs into early clinical testing from 2015 in the US and Brazil.  

4-Antibody and Ludwig jointly will own the antibody drugs while Recepta Biopharma has baged exclusive commercial rights to Brazil in return for undisclosed licensing fees. 4-Antibody will take the lead securing commercialisation partners for the antibody drugs in territories outside Brazil on behalf of itself and Ludwig. Future returns from the collaboration outside of Brazil will be shared among the three parties.

© eurobiotechnews.eu/tg

http://www.european-biotechnology-news.com/news/news/2013-01/new-cancer-collaborations.html

FinancingSwedenNorway

31.10.2014 Another biotech is leaving the European market place in favour of a US IPO. Swedish Cortendo is now planning to go public in the US after raising €8.8m in bridge financing.

FinancingUK

29.10.2014 British VC fundraiser Advent Life Sciences has raised €184m with its second fund. The money will help seed and build life sciences companies in the UK, Europe and the US, the company said.

BusinessSwitzerlandGermanyUK

28.10.2014 Swiss pharma company Novartis is selling its influenza vaccines business to Australian biopharma specialist CSL Ltd for US$275m.

PoliticsSwitzerland

23.10.2014 Just one day before its planned initial listing, Swiss Molecular Partners has cancelled its IPO. The reason: "unfavourable market conditions".

PoliticsEU

23.10.2014 Jean-Claude Juncker can breathe a sigh of relief as MEPs voted “yes” by a large majority to his team of European Union Commissioners. Previous to the vote, Juncker had shifted the EMA back to the health commissioner in response to protests.

FinancingFrance

21.10.2014 Yet another European company is looking for money on the US stock exchange – French DBV Technologies SA is all set up for its secondary listing on NASDAQ. The French biotech company hopes to rake in US$98m for its peanut allergy patches.

FinancingDenmark

18.10.2014 After raising US$220.5m (€172m) with its IPO, fast Forward Pharma’s lucky streak hits an obstacle on the road to success with shares falling 17% on its first day of trading.

M&AUKItaly

17.10.2014 Abandoned at the altar: Abbvie has dropped plans to acquire UK’s Shire following new US tax rules. This puts a stop to one of the biggest pharma mergers planned this year.

FinancingUKBelgium

15.10.2014 Bicycle Therapeutics wins €25m backing by major pharma venture capitalists for the development of a new class of oncology drugs.

FinancingGermanySwitzerlandNetherlands

13.10.2014 Biotechnology IPOs are back in fashion – German Probiodrug AG wants to raise €32m with its IPO, whilst Swiss Molecular Partners AG hopes the launch of its IPO will gain a revenue of €145m.

Events

All Events

Current issue

All issues

Product of the week

Products

Stock list

All quotes

TOP

  • THERAMETRICS0.08 CHF14.29%
  • CYTOS0.17 CHF13.33%
  • MORPHOSYS75.99 EUR4.89%

FLOP

  • EPIGENOMICS4.15 EUR-4.38%
  • EVONIK26.20 EUR-2.42%
  • PAION2.80 EUR-2.10%

TOP

  • BIOFRONTERA2.82 EUR15.6%
  • BB BIOTECH166.45 EUR11.2%
  • HBM91.50 CHF8.6%

FLOP

  • MAGFORCE5.55 EUR-19.0%
  • PAION2.80 EUR-14.6%
  • CO.DON2.65 EUR-13.1%

TOP

  • SANTHERA89.00 CHF2182.1%
  • CO.DON2.65 EUR150.0%
  • WILEX2.25 EUR81.5%

FLOP

  • CYTOS0.17 CHF-95.7%
  • MERCK KGAA71.68 EUR-41.5%
  • 4SC0.98 EUR-41.0%

No liability assumed, Date: 31.10.2014